Status:
COMPLETED
Added Value of PET/CT in Assessment of Hepatocellular Malignancy Post Radiofrequency Ablation
Lead Sponsor:
Tanta University
Conditions:
PET/CT
Hepatocellular Malignancy
Eligibility:
All Genders
40-75 years
Brief Summary
This study aims to assess the residual tumoral activity versus the well ablation of اepatocellular carcinoma (HCC) post radiofrequency ablation.
Detailed Description
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and is a leading cause of cancer-related death worldwide. It is the third most common cause of death of cancer worldwide, als...
Eligibility Criteria
Inclusion
- Age from 40 to 75 years.
- Both sexes.
- Patients with hepatocellular carcinoma (HCC) and underwent radiofrequency ablation (RFA) .
Exclusion
- Patients with past history of contrast allergy.
- Patients with blood glucose level \>200 mg/dl at the time of the study.
- High serum creatinine\> 2 mg / dl.
- Small lesions \< 10 mm.
- Well differentiated hepatocellular carcinoma (HCC) lesions by pathology.
Key Trial Info
Start Date :
December 30 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 30 2025
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT06960031
Start Date
December 30 2024
End Date
April 30 2025
Last Update
May 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tanta University
Tanta, El-Gharbia, Egypt, 31527